评价24价肺炎球菌多糖结合疫苗在18周岁及以上人群中接种的安全性和耐受性的I期临床试验和评价24价肺炎球菌多糖结合疫苗在65周岁及以上人群中接种的安全性和免疫原性的Ⅱ期临床试验
[Translation] A phase I clinical trial to evaluate the safety and tolerability of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 18 years and above, and a phase II clinical trial to evaluate the safety and immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 65 years and above
Ⅰ期:评价24价肺炎球菌多糖结合疫苗在18周岁及以上人群中接种的安全性和耐受性。Ⅱ期:评价24价肺炎球菌多糖结合疫苗在65周岁及以上人群中接种的安全性和免疫原性。
[Translation] Phase I: To evaluate the safety and tolerability of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 18 years and above. Phase II: To evaluate the safety and immunogenicity of 24-valent pneumococcal polysaccharide conjugate vaccine in people aged 65 years and above.
评价13价肺炎球菌多糖结合疫苗在2月龄(最小满6周龄)及以上健康人群中接种的安全性、耐受性和初步探索免疫原性的Ⅰ期临床试验
[Translation] A phase I clinical trial to evaluate the safety, tolerability and preliminary exploration of immunogenicity of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) and above
评价13价肺炎球菌多糖结合疫苗在2月龄(最小满6周龄)及以上健康人群中的安全性、耐受性和初步探索免疫原性。
[Translation] To evaluate the safety, tolerability and preliminary immunogenicity of 13-valent pneumococcal polysaccharide conjugate vaccine in healthy people aged 2 months (minimum 6 weeks) and above.
100 Clinical Results associated with Shandong Kunli Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shandong Kunli Biopharmaceutical Co., Ltd.
100 Deals associated with Shandong Kunli Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Shandong Kunli Biopharmaceutical Co., Ltd.